Keywords: biogen, galiximab, enters, ph, iii, cancer, trial

Biogen's galiximab enters Ph III cancer trial

Article | 05 February 2007

Print This

US drugmaker Biogen Idec says it has begun a Phase III trial of an investigational anti-CD80 monoclonal antibody, named galiximab, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in